Head-To-Head Review: CareDx (NASDAQ:CDNA) vs. CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies (NASDAQ:CLGN) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CollPlant Biotechnologies and CareDx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1	1	0	0	1.50
CareDx	0	5	3	0	2.38

CollPlant Biotechnologies currently has a consensus price target of $120.00, suggesting a potential upside of 3,318.80%. CareDx has a consensus price target of $54.00, suggesting a potential downside of 15.19%. Given CollPlant Biotechnologies’ higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than CareDx.

Volatility & Risk

CollPlant Biotechnologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, CareDx has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500.

Valuation & Earnings

This table compares CollPlant Biotechnologies and CareDx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37 million	2.80	-$11.49 million	($13.59)	-0.26
CareDx	$458.09 million	7.19	-$21.35 million	$2.07	30.76

CollPlant Biotechnologies has higher earnings, but lower revenue than CareDx. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by insiders. Comparatively, 2.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares CollPlant Biotechnologies and CareDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%
CareDx	24.23%	2.87%	2.17%

Summary

CareDx beats CollPlant Biotechnologies on 10 of the 14 factors compared between the two stocks.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

About CareDx

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.